Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus
Bibliographic record
Abstract
Abstract Background: Luspatercept is an erythroid-maturation agent approved to treat anemia in patients (pts) with transfusion-dependent (TD) lower-risk myelodysplastic syndromes (LR-MDS) who are erythropoiesis-stimulating agent (ESA)–naive or –exposed. Luspatercept improved red blood cell (RBC) transfusion independence (RBC-TI) in pts in the COMMANDS and MEDALIST studies, with most pts titrating to the maximum-approved dose (1.75 mg/kg). This open-label, phase 3b MAXILUS study (NCT06045689) is being conducted to evaluate luspatercept initiated at the maximum-approved dose in pts with TD LR-MDS. Preliminary results indicated that luspatercept was well-tolerated, with no new safety signals observed and notable ease of administration. We report updated efficacy and safety outcomes from the preplanned interim analysis of the MAXILUS study, with >75% of the study population evaluable based on the 24-week treatment phase. Methods: Eligible pts with non-del(5q) LR-MDS (per IPSS-R) were ≥18 years of age, TD (required ≥1 unit of packed RBCs ≤8 weeks before treatment), and had an ECOG PS score ≤2. Pts were enrolled into cohort 1 (ESA-naive) or cohort 2 (ESA-relapsed/refractory or intolerant [R/R/I]) to receive subcutaneous luspatercept 1.75 mg/kg every 3 weeks. The primary endpoint was RBC-TI ≥8 weeks, with a concurrent mean hemoglobin increase of ≥1.0 g/dL from Weeks 1 to 24. Secondary endpoints included RBC-TI ≥12 weeks (Weeks 1-24) and safety. The data cutoff was April 14, 2025. Results: At data cutoff, 105 pts (ESA-naive, n=52; ESA-R/R/I, n=53) composed the safety population of pts who received ≥1 dose of luspatercept. Median (IQR) duration of follow-up was 5.8 months (3.3-8.2) in the ESA-naive cohort and 7.4 months(5.6-9.2) in the ESA-R/R/I cohort. The median age was 76.0 years in both the ESA-naive and ESA-R/R/I cohorts, and 73.1% (38/52) and 90.6% (48/53) of pts were from Europe, respectively. SF3B1 mutation was present in 51.9% (27/52; ESA-naive) and 56.6% (30/53; ESA-R/R/I) of pts; 40.4% (21/52) and 39.6% (21/53) of pts had ring sideroblast (RS)-negative status; and 73.1% (38/52) and 43.4% (23/53) of pts had baseline serum erythropoietin (sEPO) ≤200 IU/L, respectively. ESA-naive pts: 86.5% of pts were on treatment at data cutoff; 13.5% discontinued treatment, primarily due to withdrawal by the pt (5.8%). Median (range) treatment duration was 25.5 weeks (2.1-50.0). There were 11.5% of pts who required ≥1 dose reduction; 36.5% had ≥1 dose delay. Treatment-emergent adverse events (TEAEs) occurred in 78.8% of pts; 19.2% were treatment-related. Grade 3/4 TEAEs occurred in 34.6% of pts; 3.8% were treatment-related. TEAEs leading to drug interruption occurred in 5.8% of pts. No thromboembolic events (TEEs) were observed, and no pts experienced disease progression to acute myeloid leukemia (AML) or higher-risk MDS (HR-MDS). Among pts who completed the 24-week efficacy-evaluable period at data cutoff (n=30), the primary endpoint was achieved in 73.3% of pts. RBC-TI ≥12 weeks was achieved in 70.0% of all pts, in 61.5% of pts with RS-negative status, and in 85.0% of pts with baseline sEPO ≤200 IU/L. ESA-R/R/I pts: 60.4% of pts were on treatment at data cutoff; 39.6% of pts discontinued treatment, primarily due to a lack of efficacy (13.2%). Median (range) treatment duration was 27.1 weeks (2.1-72.9). There were 13.2% of pts who required ≥1 dose reduction; 39.6% had ≥1 dose delay. TEAEs occurred in 92.5% of pts; 37.7% were treatment-related. Grade 3/4 TEAEs occurred in 47.2% of pts; 5.7% were treatment-related. TEAEs leading to drug interruption occurred in 17.0% of pts. No TEEs were observed, and no pts experienced disease progression to AML; 1 pt experienced disease progression to HR-MDS. Among pts who completed the 24-week efficacy-evaluable period at data cutoff (n=49), the primary endpoint was achieved in 65.3% of pts. RBC-TI ≥12 weeks was achieved in 49.0% of all pts, in 33.3% of pts with RS-negative status, and in 61.9% of pts with baseline sEPO ≤200 IU/L . Conclusions: Starting luspatercept at the maximum-approved dose of 1.75 mg/kg was well-tolerated, with no new safety signals. The high rate of RBC-TI ≥12 weeks in ESA-naive pts suggests that early use of luspatercept may contribute to clinical benefit. In this preplanned interim analysis, luspatercept demonstrated efficacy among pts with LR-MDS, including in those with RS-negative status and baseline sEPO ≤200 IU/L.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.005 | 0.003 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.003 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.002 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.005 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".